Miloš Pešek

3.0k total citations · 1 hit paper
110 papers, 2.4k citations indexed

About

Miloš Pešek is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Miloš Pešek has authored 110 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Pulmonary and Respiratory Medicine, 66 papers in Oncology and 22 papers in Molecular Biology. Recurrent topics in Miloš Pešek's work include Lung Cancer Treatments and Mutations (62 papers), Lung Cancer Research Studies (31 papers) and Colorectal Cancer Treatments and Studies (22 papers). Miloš Pešek is often cited by papers focused on Lung Cancer Treatments and Mutations (62 papers), Lung Cancer Research Studies (31 papers) and Colorectal Cancer Treatments and Studies (22 papers). Miloš Pešek collaborates with scholars based in Czechia, Germany and Hungary. Miloš Pešek's co-authors include Jaromı́r Roubec, Marek Minárik, Lucie Benešová, Ondřej Fiala, Jindřich Fínek, Ondřej Topolčan, Rodryg Ramlau, Piotr Serwatowski, Georgy M. Manikhas and Joachim von Pawel and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Osteoporosis International.

In The Last Decade

Miloš Pešek

99 papers receiving 2.3k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

2007 706 citations Miloš Pešek et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Miloš Pešek Czechia	21	1.7k	1.6k	650	408	133	110	2.4k
Daniel T. Milton United States	16	1.9k 1.1×	1.6k 1.0×	587 0.9×	383 0.9×	125 0.9×	27	2.4k
Isabel Bover Spain	13	1.3k 0.8×	1.3k 0.8×	401 0.6×	247 0.6×	204 1.5×	48	2.1k
Michael Offin United States	23	1.5k 0.8×	1.1k 0.7×	550 0.8×	492 1.2×	240 1.8×	97	2.1k
Patrick Peterson United States	21	2.2k 1.3×	1.8k 1.1×	472 0.7×	310 0.8×	166 1.2×	55	2.6k
Katsuhiro Masago Japan	25	1.5k 0.9×	1.2k 0.7×	453 0.7×	324 0.8×	148 1.1×	119	2.1k
Francesco Facchinetti Italy	25	1.2k 0.7×	1.1k 0.7×	827 1.3×	386 0.9×	112 0.8×	79	2.1k
Jessica Menis Italy	21	1.1k 0.6×	1.2k 0.7×	381 0.6×	363 0.9×	145 1.1×	76	1.9k
Antonio Galvano Italy	24	800 0.5×	996 0.6×	475 0.7×	540 1.3×	154 1.2×	96	1.8k
Joo Hang Kim South Korea	27	1.9k 1.1×	1.9k 1.1×	789 1.2×	426 1.0×	326 2.5×	91	3.0k
Ana C. Xavier United States	13	1.1k 0.6×	1.1k 0.6×	518 0.8×	333 0.8×	123 0.9×	51	1.8k

Countries citing papers authored by Miloš Pešek

Since Specialization

Citations

This map shows the geographic impact of Miloš Pešek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miloš Pešek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miloš Pešek more than expected).

Fields of papers citing papers by Miloš Pešek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miloš Pešek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miloš Pešek. The network helps show where Miloš Pešek may publish in the future.

Co-authorship network of co-authors of Miloš Pešek

This figure shows the co-authorship network connecting the top 25 collaborators of Miloš Pešek. A scholar is included among the top collaborators of Miloš Pešek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miloš Pešek. Miloš Pešek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ondič, Ondřej, et al.. (2022). Patients with neuregulin 1 (NRG1) rearranged cancer are suitable for the theranostic approach and targeted therapy. Klinicka onkologie. 35(4). 271–275. 3 indexed citations

Fiala, Ondřej, Jan Baxa, Martin Svatoň, et al.. (2022). Combination of Circulating Tumour DNA and¹⁸F-FDG PET/CT for Precision Monitoring of Therapy Response in Patients With Advanced Non-small Cell Lung Cancer: A Prospective Study. Cancer Genomics & Proteomics. 19(2). 270–281. 11 indexed citations

Svatoň, Martin, et al.. (2021). Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy. Anticancer Research. 41(4). 2053–2058. 4 indexed citations

Brat, Kristián, Jana Skřičková, Miloš Pešek, et al.. (2020). Real‐life effectiveness of first‐line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry. Thoracic Cancer. 11(11). 3346–3356. 7 indexed citations

Baxa, Jan, Martin Sedlmair, Thomas Flohr, et al.. (2018). Single-source Dual-energy CT as a Part of ¹⁸F-FDG PET/CT: Direct Comparison of Iodine-related and Metabolic Parameters in Non-small Cell Lung Cancer. Anticancer Research. 38(7). 4131–4137. 5 indexed citations

Fiala, Ondřej, Petr Hošek, Miloš Pešek, et al.. (2017). Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed. Neoplasma. 64(4). 605–610. 3 indexed citations

Pešek, Miloš & Jan Mužı́k. (2017). Small-cell lung cancer: epidemiology, diagnostics and therapy. Vnitřní lékařství. 63(11). 876–883. 3 indexed citations

Pešek, Miloš, et al.. (2017). P1.04-012 Single Center Experience with Nivolumab Administration in NSCLC Patients from EAP Program. Journal of Thoracic Oncology. 12(1). S602–S603.

Fiala, Ondřej, et al.. (2017). Immunotherapy in the Treatment of Lung Cancer. Klinicka onkologie. 30(Suppl 3). 3S22–3S31. 9 indexed citations

10.

Kulda, Vlastimil, Martin Svatoň, Petr Mukenšnábl, et al.. (2017). Predictive relevance of miR‑34a, miR‑224 and miR‑342 in patients with advanced squamous cell carcinoma of the lung undergoing palliative chemotherapy. Oncology Letters. 15(1). 592–599. 5 indexed citations

11.

Pešek, Miloš. (2016). New WHO classification of lung tumours. 10(1). 20–24. 1 indexed citations

12.

Svatoň, Martin, Miloš Pešek, Z Chudáček, & Hana Vošmiková. (2015). Current Two EGFR Mutations in Lung Adenocarcinoma – Case Report. Klinicka onkologie. 28(2). 134–137. 7 indexed citations

13.

Fiala, Ondřej, Miloš Pešek, Jindřich Fínek, Zbyněk Bortlíček, & Ondřej Topolčan. (2014). P17. Prognostic significance of serum tumor markers in patients with advanced-stage NSCLC treated with pemetrexed-based chemotherapy. Translational Lung Cancer Research. 3(5). 1 indexed citations

14.

Fiala, Ondřej, Miloš Pešek, Jindřich Fínek, et al.. (2012). Second line treatment in advanced non-small cell lung cancer (NSCLC): Comparison of efficacy of Erlotinib and chemotherapy. Neoplasma. 60(2). 129–134. 5 indexed citations

15.

Pešek, Miloš, et al.. (2009). Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.. PubMed. 29(7). 2767–73. 33 indexed citations

16.

Obermajer, Nataša, et al.. (2009). Levels of Cathepsins S and H in Pleural Fluids of Inflammatory and Neoplastic Origin. The International Journal of Biological Markers. 24(1). 47–51. 5 indexed citations

17.

Crinò, Lucio, Petr Zatloukal, Martin Reck, et al.. (2007). B3-04: Gefitinib (IRESSA) versus vinorelbine in chemonaïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized Phase II study. Journal of Thoracic Oncology. 2(8). S341–S341. 19 indexed citations

18.

Zatloukal, Petr, Luboš Petruželka, Milada Zemanová, et al.. (2003). Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin in Stage IIIb and IV Non Small Lung Cancer: A phase III Randomized Trial. Lung Cancer. 41. 41 indexed citations

19.

Zatloukal, Petr, Péter Magyar, Jacek Jassem, et al.. (1998). Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study. Lung Cancer. 22(3). 243–250. 15 indexed citations

20.

Elleder, M., et al.. (1969). Isoenzymes of lactate dehydrogenase in human lung tissue and in malignant lung tumours.. PubMed. 16(6). 645–50.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact